Tekla Life Sciences Stock Z Score
| HQL Stock | USD 13.18 0.22 1.70% |
Tekla | Z Score |
Tekla Life Sciences Company Z Score Analysis
Tekla Life's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Tekla Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Tekla Life is extremely important. It helps to project a fair market value of Tekla Stock properly, considering its historical fundamentals such as Z Score. Since Tekla Life's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tekla Life's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tekla Life's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
According to the company's disclosures, Tekla Life Sciences has a Z Score of 0.0. This is 100.0% lower than that of the Capital Markets sector and 100.0% lower than that of the Financials industry. The z score for all United States stocks is 100.0% higher than that of the company.
Tekla Life Current Valuation Drivers
We derive many important indicators used in calculating different scores of Tekla Life from analyzing Tekla Life's financial statements. These drivers represent accounts that assess Tekla Life's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Tekla Life's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 504.6M | 350.8M | 352.8M | 423.1M | 380.8M | 243.8M | |
| Enterprise Value | 505.9M | 350.8M | 352.8M | 423.1M | 380.8M | 244.1M |
Tekla Life ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tekla Life's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tekla Life's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Tekla Fundamentals
| Return On Equity | 0.0128 | ||||
| Return On Asset | -0.0032 | ||||
| Profit Margin | 21.43 % | ||||
| Operating Margin | (0.66) % | ||||
| Current Valuation | 363.68 M | ||||
| Shares Outstanding | 28.06 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 34.47 % | ||||
| Number Of Shares Shorted | 96.46 K | ||||
| Price To Earning | 2.84 X | ||||
| Price To Book | 0.79 X | ||||
| Price To Sales | 91.38 X | ||||
| Revenue | 86.69 M | ||||
| Gross Profit | 3.98 M | ||||
| EBITDA | 22.35 M | ||||
| Net Income | 85.3 M | ||||
| Cash And Equivalents | 292.4 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 888.61 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 1.34 X | ||||
| Book Value Per Share | 16.38 X | ||||
| Cash Flow From Operations | (12.8 M) | ||||
| Short Ratio | 0.38 X | ||||
| Earnings Per Share | 3.04 X | ||||
| Beta | 0.72 | ||||
| Market Capitalization | 363.68 M | ||||
| Total Asset | 460.58 M | ||||
| Retained Earnings | 44.13 M | ||||
| Annual Yield | 0.15 % | ||||
| Five Year Return | 8.83 % | ||||
| Net Asset | 460.58 M | ||||
| Last Dividend Paid | 1.66 |
About Tekla Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tekla Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tekla Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tekla Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Tekla Life Piotroski F Score and Tekla Life Valuation analysis. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.425 | Dividend Share 1.66 | Earnings Share 3.04 | Revenue Per Share | Quarterly Revenue Growth 0.07 |
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.